Core Viewpoint - Baotai reported a revenue of 934 million yuan for 2025, marking a year-on-year increase of 25.64%, while the net loss attributable to the parent company was 336 million yuan, an improvement from a net loss of 510 million yuan in the previous year [1] Group 1: Financial Performance - The company achieved an operating revenue of 934 million yuan in 2025, reflecting a growth of 25.64% compared to the previous year [1] - The net loss attributable to the parent company was 336 million yuan, which is an improvement from the net loss of 510 million yuan in the same period last year [1] Group 2: Market Expansion - Baotai actively expanded its market during the reporting period, with sales of Adalimumab injection (Geleli®) and Tocilizumab injection (Shiruili®) steadily increasing compared to the previous year [1] - The company launched Ustekinumab injection (STARJEMZA®) in the United States during the reporting period, contributing to growth in licensing income and sales revenue [1]

Core Viewpoint - The company Baotai (688177.SH) reported a revenue of 934 million yuan for the fiscal year 2025, marking a year-on-year growth of 25.64%, despite a net loss attributable to shareholders of 336 million yuan [1] Financial Performance - The company achieved a total revenue of 934 million yuan, reflecting a 25.64% increase compared to the previous year [1] - The net profit attributable to shareholders was -336 million yuan, with a net profit excluding non-recurring items at -430 million yuan [1] - Basic earnings per share were -0.81 yuan, and the weighted average return on net assets was -62.32% [1] Profitability Improvement - The total profit loss decreased by 174.15 million yuan compared to the same period last year [1] - The net profit attributable to shareholders improved by 173.86 million yuan year-on-year, primarily due to continuous revenue growth [1] Market Expansion - The company actively expanded its market, with sales of Adalimumab injection (Geleli®) and Tocilizumab injection (Shirili®) steadily increasing compared to the previous year [1] - The launch of Ustekinumab injection (STARJEMZA®) in the U.S. contributed to growth in licensing income and sales revenue [1]